SEMA3A and neoplasm: These findings underscore the clinical relevance of SEMA3A in ovarian cancer prognosis and highlight its potential as a biomarker and therapeutic target not only in mitigating tumor progression and metastasis but also in other ovarian-associated conditions, such as DOR.